If you look at the data as a whole and especially the six studies we cite in our editorial the findings suggest that the cardiovascular and metabolic benefits of GLP-1 drugs extend beyond weight loss, indicating other mechanisms, such as anti-inflammatory or kidney and liver effects, may play a major role
In Phase 2 research, this pharmacological profile translated into the largest average weight reductions ever reported for a once-weekly peptide, catalyzing widespread interest among endocrinologists, obesity researchers, and metabolic-disease scientists
10.1186/s13048-019-0555-8 100 ThomsenR
And heres the answer: oral GLP-1 medications work extremely well, but comparing pills with injections is not as simple as it sounds
Because it is subject to somatostatin feedback, the risk of pushing GH to supraphysiological levels is theoretically lower